Cure51
Cure51 is a Paris-based TechBio company building a global multi-omics database of exceptional cancer survivors through the Rosalind Study across 112+ oncology centers in 63+ countries, using proprietary Elio AI to discover novel therapeutic targets for pharmaceutical partners.
- Company typePrivate
- Founded2022
- HeadquartersParis, France
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Cure51 does
Cure51 is a Paris-based TechBio company founded in March 2022 that has built one of the largest global oncology networks focused on "exceptional cancer survivors" — patients who survive highly lethal cancers far beyond medical expectations. The company's flagship program, the Rosalind Study, is a retrospective, multi-center, case-control study that recruits survivors and matched controls through 112+ partner oncology centers across 63+ countries, with biological sample processing centralized at a laboratory housed within the Gustave Roussy Cancer Campus. Three cancer cohorts are the focus: metastatic pancreatic ductal adenocarcinoma, glioblastoma IDHwt, and extensive small cell lung cancer. As of January 2026, Cure51 had collected 1,064 patient samples and analyzed over 1,000 exceptional survivors, identifying 10+ consistent survival characteristics and multiple novel therapeutic targets now advancing into in vitro testing.
The company's core technical platform comprises three components: the Rosalind Study clinical operations and biobank, the Patient Profile Platform (PPP) electronic clinical record file system, and Elio, a proprietary multi-agent AI system that cross-references internal multi-omics datasets (genomics, single-cell and spatial transcriptomics, proteomics, microbiomics) with external peer-reviewed scientific literature to generate therapeutic hypotheses. Multi-omics profiling is performed using state-of-the-art technologies including 10X Genomics Xenium/Visium spatial transcriptomics, 10X Genomics Flex single-cell transcriptomics, whole exome sequencing, 16s RNA microbiomics, and FFPE mass-spectrometry proteomics. Cure51 monetizes through B2B research partnerships with oncology centers and pharmaceutical companies under a professional services model, with first therapeutic targets entering in vitro testing in early 2026 as the company positions for pharmaceutical co-development partnerships. The company holds ISO/IEC 27001:2022 and French HDS v2.0 certifications (both January 2026), is backed by Sofinnova Partners, Hitachi Ventures, and Life Extension Ventures following a $16.3M March 2024 funding round, and operates with a team of 59 collaborators spanning 20 nationalities.
Cure51 firmographics
Firmographics- Name
- Cure51
- Legal name
- CURE51
- Website
- https://cure51.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Cure51 is a Paris-based TechBio company building a global multi-omics database of exceptional cancer survivors through the Rosalind Study across 112+ oncology centers in 63+ countries, using proprietary Elio AI to discover novel therapeutic targets for pharmaceutical partners.
- Ownership category
- akta.pro rank
Cure51 industry classification
Industry- Product category
- Oncology Research Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Medical and Diagnostic Laboratories (62151)
- SIC
- Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)
- akta.pro secondary industries
- Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Biomarker Discovery & Validation (omics, assay feasibility, clinical validation) (HLAAAMAA), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
Keywords
Where Cure51 is headquartered
LocationHeadquarters
- HQ city
- Paris
- HQ country
- France
- HQ region
- Europe
Offices1 record
Markets served
Cure51 business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Research Partnerships and Grants: Cure51 operates primarily through research partnerships with oncology centers and pharmaceutical companies. The company collaborates with pharma partners for therapeutic target validation and drug discovery programs. As a pre-commercial research organization, revenue is generated through research grants, strategic partnerships, and pharmaceutical collaborations rather than product sales.
Go-to-market motion3 records
Distribution channels2 records
Marketing channels7 records
Cure51 product offering
Product offeringCore offering
Cure51 operates the Rosalind Study, a retrospective, multi-center, case-control clinical study that profiles exceptional cancer survivors ("outliers") across three highly lethal cancer cohorts (metastatic pancreatic ductal adenocarcinoma, glioblastoma IDHwt, and extensive small-cell lung cancer). The company collects clinical data and biological samples from survivors worldwide, performs comprehensive multi-omics profiling at its central lab, and applies its proprietary Elio AI system to identify novel therapeutic targets. The company also develops pharmaceutical partnerships for drug discovery and is testing first therapeutic targets in vitro.
Product overview
Cure51 is a techbio company operating as a unified platform centered on the Rosalind Study - a global clinical research initiative studying exceptional cancer survivors. The platform consists of the Rosalind Study (core clinical research program), the Patient Profile Platform (PPP - eCRF tool for data collection), and Elio (proprietary multi-agent AI system for data analysis). Biological sample processing is handled through Cure51's central lab at Gustave Roussy Cancer Campus, which provides comprehensive multi-omics profiling capabilities. The company is expanding into therapeutic target validation with in vitro testing and pharmaceutical partnerships.
Differentiator
Problem solved
Functional benefit
Products and services
- Rosalind Study A retrospective, multi-center, case-control clinical study comparing patients with long-term survival to matched controls across three major cancer cohorts (metastatic pancreatic ductal adenocarcinoma, glioblastoma IDHwt, and extensive small-cell lung cancer). The study builds a large-scale clinical and multi-omics database of exceptional cancer survivors to discover biomarkers, resistance signatures, and therapeutic targets.
- Elio AI System Cure51's proprietary multi-agent AI system that connects clinical, molecular, and scientific data at scale. Elio accelerates cancer discovery by aggregating and analyzing information across clinical operations, scientific teams, internal multi-omics datasets, and external research to generate biological hypotheses and identify therapeutic targets.
- Cure51 Central Lab Services State-of-the-art multi-omics laboratory processing at Gustave Roussy Cancer Campus. Capabilities include spatial transcriptomics (10X Genomics Xenium/Visium), single-cell transcriptomics (10X Genomics Flex), whole exome sequencing, microbiomics (16s RNA), and proteomics (FFPE mass-spectrometry) for comprehensive biological profiling of patient samples from exceptional cancer survivors.
Quantifiable outcome
- Identified 10+ characteristics that consistently appear in exceptional cancer survivors
- +3 more outcomes
Companies that use Cure51
Customer profileNamed customers9 records
Segments3 records
Ideal customer profiles2 records
Cure51 technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability7 records
Feature5 records
Cure51 partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered major and core.
- Mediclinic Middle East City HospitalmajorUAE's leading oncology institution with cutting-edge radiotherapy technology and multidisciplinary cancer care team. Collaborating with Cure51 for the Rosalind Study launch in Dubai under Dr. Shaheenah Dawood's leadership.
- ExplicytemajorSelected by Cure51 to participate in the world's largest study analyzing biological mechanisms of exceptional cancer survivors. Based at the Bergonié Institute with access to a unique technology platform in Europe.
- NVIDIAcoreCure51 partnered with NVIDIA to accelerate research into exceptional cancer survivors using AI-powered tools. The company is part of NVIDIA's DGX Cloud Innovation Lab and Inception Program, using AI-accelerated computing to support multi-omics database development and sample analysis scaling across the global network of cancer centers.
- AWS (Amazon Web Services)coreAWS provides cloud infrastructure hosting for Cure51's applications and health data. AWS is HDS and ISO/IEC 27001:2022 certified and provides physical infrastructure (Activity 1-2) for the company's information system. Servers are located in Europe (France and Germany).
- Theodo CloudcoreTheodo Cloud provides hosting and managed services (Activities 3-5) for Cure51's health data infrastructure. The company is HDS certified and supports the operation of the information system containing personal health data.
- Gustave Roussy InstitutecoreOne of Europe's leading cancer centers serving as the central lab location for the Rosalind Study. Houses Cure51's central lab for processing biological samples with comprehensive multi-omics profiling.
- Centre Léon BérardcoreLeading French cancer center and lead partner oncology center in Cure51's international network. Contributes to the Rosalind Study by identifying and enrolling exceptional cancer survivors.
- Vall d'Hebron Institute of Oncology (VHIO)coreLeading Spanish cancer research institute and lead partner oncology center. Contributing scientific leadership including Dr. Josep Tabernero as part of the Scientific Steering Committee.
- Charité Universitätsmedizin BerlincoreOne of Europe's largest university hospitals and lead partner oncology center. Contributing scientific leadership including Dr. Ulrich Keilholz as part of the Scientific Steering Committee.
- 115+ Partner Oncology CentersmajorGlobal network of clinical research centers including major institutions like NTUH (Taiwan), Well Cornell, Addenbrooke's Hospital (NHS UK), Institut Bergonié, and many others across 63 countries participating in the Rosalind Study.
Scale indicators8 records
Recent moves6 records
Expansion highlights7 records
Cure51 competitors and assessment
Company assessmentDirect peers
- Owkin: French AI-biotech company applying multi-modal data and federated learning to oncology drug discovery and patient stratification. Most comparable European peer: similar Paris-based techbio model, pharma partnerships, and focus on multi-omics for target discovery.
- Recursion Pharmaceuticals: AI-native drug discovery company combining high-throughput biology with machine learning to identify novel therapeutic targets. Comparable techbio platform model and pharma partnerships, though broader therapeutic scope.
- Exscientia: AI-driven precision medicine company with a patient-centric drug discovery platform including patient-derived data for target identification. Directly comparable as an AI-drug-discovery platform with pharma partnerships.
- Insitro: AI-driven drug discovery platform combining data generation, machine learning, and biology to identify targets. Comparable techbio model using multi-modal data and pharma collaborations to advance pipelines.
- Explicyte: French immuno-oncology CRO and translational research company that Cure51 already partnered with for the Rosalind Study. Directly comparable as a Bordeaux-based oncology biomarker and target discovery service provider.
Broad incumbents
- Tempus Labs: US AI-driven precision medicine company building one of the world's largest multi-modal oncology datasets. Comparable through multi-omics profiling and pharma data-licensing model, but operates at much larger scale across all of oncology.
- Foundation Medicine: Roche-owned oncology molecular profiling company providing comprehensive genomic profiling of tumors. Comparable through multi-omics oncology data, but focuses on diagnostics/companion Dx rather than survivor-biology target discovery.
Emerging players
- Schrödinger: Computational chemistry and physics-based drug discovery platform serving pharma. Comparable AI-for-drug-discovery model with SaaS + partnered programs, though more focused on molecular design than patient-derived target ID.
- Personalis: Cancer genomics company specializing in tumor profiling via whole-genome sequencing and ImmunoID platform. Comparable through deep molecular profiling of cancer patients, though narrower focus on ctDNA and MRD applications.
- Lantern Pharma: AI-driven oncology drug development company using RADR platform to identify responder populations and rescue/advance oncology therapeutics. Comparable AI-oncology platform model with focus on patient-derived data.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Cure51 social profiles
Digital presenceCure51 compliance and trust
Trust signalCompliance2 records
Cure51 financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cure51 leadership team
Management profileNumber of profiles
Profiles8 records
Cure51 funding detail
Funding detailFunding overview
Funding rounds1 record
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cure51 M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cure51
What does Cure51 do?
Cure51 operates the Rosalind Study, a retrospective, multi-center, case-control clinical study that profiles exceptional cancer survivors ("outliers") across three highly lethal cancer cohorts (metastatic pancreatic ductal adenocarcinoma, glioblastoma IDHwt, and extensive small-cell lung cancer). The company collects clinical data and biological samples from survivors worldwide, performs comprehensive multi-omics profiling at its central lab, and applies its proprietary Elio AI system to identify novel therapeutic targets. The company also develops pharmaceutical partnerships for drug discovery and is testing first therapeutic targets in vitro.
Is Cure51 a public or private company?
Cure51 is a private company. It is classified as venture growth investor backed and is currently operating.
When was Cure51 founded?
Cure51 was founded in 2022. It employs 51 to 100 people.
Where is Cure51 based?
Cure51 is headquartered in Paris, France, in the Europe region.
How does Cure51 make money?
One revenue line is on record: research Partnerships and Grants.
Who are Cure51's main competitors?
Direct peers on record are Owkin, Recursion Pharmaceuticals, Exscientia, Insitro and Explicyte. Broad incumbents are Tempus Labs and Foundation Medicine. Emerging players are Schrödinger, Personalis and Lantern Pharma.
Does Cure51 have an API?
No public API is recorded for Cure51.
What industry is Cure51 in?
Cure51's product category is Oncology Research Services. Its primary akta.pro industry code is HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery), with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 8731.